[Efficacy of the Serigaya Methamphetamine Relapse Prevention Program (SMARPP): for patients with drug use disorder: A study on factors influencing 1-year follow-up outcomes].
OBJECTIVE
The purpose of this study was to evaluate the efficacy of the Serigaya Methamphetamine Relapse Prevention Program (SMARPP), which is the workbook-based group therapy for individuals with drug dependence, through investigating 1-year follow-up outcomes.


METHODS
The sample was drawn from 231 outpatients diagnosed as DSM-IV substance use disorder, who had firstly consulted the drug dependence clinic of the Center Hospital, National Center of Neurology and Psychiatry between September 2009 and June 2013. Of the 231 potential subjects, 79 had participated in SMARPP at least once, and finally 37 who had continued contact this clinic for more than 1 year after due-day of finishing the first SMARPP course were determined as the subjects. We collected the outcome information retrospectively based on clinical records.


RESULTS
At the 1-year follow-up point, 67.6% of the subjects had continued abstinent at least for a month, and 60% of them had continued full-abstinent for more than 1 year. One of the factors which influenced their abstinence was "having no experience of using new psychoactive substances" (p = 0.029). As for 70.3% of subjects, drug-use frequency decreased and the only factor for their improvement was "participating in SMARPP many times" (p = 0.040). Of the subjects, 23 patients corresponded to methamphetamine use disorder, and 65.2% of them had continued abstinent at least for a month at the 1-year follow-up point. Additionally, 60% of them had continued full-abstinent for more than 1 year.


CONCLUSIONS
Our study demonstrated possible effectiveness of SMARPP for patients with drug use disorder, especially methamphetamine-use-disorder. The factors of abstinence or decrease of drug-use frequency may be to participate in SMARPP many times, not to abuse "not illegal" drugs such as new psychoactive substances or hypnotics/anxiolytics and to continue treatment for more than 1 year after due-day of finishing the program.
Yuko
Y
Tanibuchi
Toshihiko
T
Matsumoto
Fumi
F
Imamura
Asako
A
Wakabayashi
Hiraku
H
Kawachi
Emi
E
Hikitsuchi
Ayumi
A
Takano
Masako
M
Yonezawa
Takashi
T
Kato
Misako
M
Yamada
Aya
A
Wachi
Mai
M
Aboshi
Kiyoshi
K
Wada
D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008694:Methamphetamine / Q000627:therapeutic use*; D010045:Outpatients; D011615:Psychotherapy, Group / Q000379:methods; D012008:Recurrence; D055502:Secondary Prevention / Q000379:methods; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000517:prevention & control*; D016896:Treatment Outcome
D008694:Methamphetamine